Ombitasvir
Clinical data | |
---|---|
Trade names |
|
Other names | ABT-267 |
License data | |
Routes of administration | By mouth (tablets) |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Not determined |
Protein binding | ~99.9% |
Metabolism | Amide hydrolysis followed by oxidation |
Onset of action | ~4 to 5 hours |
Elimination half-life | 21 to 25 hours |
Excretion | Mostly with feces (90.2%) |
Identifiers | |
| |
JSmol) | |
| |
|
Ombitasvir is an
Viekira Pak for the treatment of HCV genotype 1,[1][2] and with paritaprevir and ritonavir in the product Technivie for the treatment of HCV genotype 4.[3][4]
Ombitasvir is an
NS5A.[5]
See also
References
- ^ "VIEKIRA PAK™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets), for Oral Use. Full Prescribing Information" (PDF). AbbVie Inc., North Chicago, IL 60064. Retrieved 30 July 2015.
- ^ "FDA approves Viekira Pak to treat hepatitis C". Food and Drug Administration. December 19, 2014.
- ^ "TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) Tablets, for Oral Use. Full Prescribing Information" (PDF). AbbVie Inc., North Chicago, IL 60064. Archived from the original (PDF) on 19 January 2019. Retrieved 28 July 2015.
- ^ "FDA approves Technivie for treatment of chronic hepatitis C genotype 4". Food and Drug Administration. July 24, 2015.
- PMID 24720703.
Further reading
- Grebely J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster GR, et al. (November 2018). "Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials". Open Forum Infectious Diseases. 5 (11): ofy248. PMID 30430131.
- Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, et al. (June 2017). "Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study". The Lancet. Gastroenterology & Hepatology. 2 (6): 427–434. PMID 28497758.